Cargando…
Both anti-inflammatory and antiviral properties of novel drug candidate ABX464 are mediated by modulation of RNA splicing
ABX464 is a first-in-class, clinical-stage, small molecule for oral administration that has shown strong anti-inflammatory effects in the DSS-model for inflammatory bowel disease (IBD) and also prevents replication of the HIV virus. ABX464 which binds to cap binding complex (CBC) has demonstrated sa...
Autores principales: | Vautrin, Audrey, Manchon, Laurent, Garcel, Aude, Campos, Noëlie, Lapasset, Laure, Laaref, Abdelhamid Mahdi, Bruno, Roman, Gislard, Marie, Dubois, Emeric, Scherrer, Didier, Ehrlich, J Hartmut, Tazi, Jamal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349857/ https://www.ncbi.nlm.nih.gov/pubmed/30692590 http://dx.doi.org/10.1038/s41598-018-37813-y |
Ejemplares similares
-
ABX464 (Obefazimod) Upregulates miR-124 to Reduce Proinflammatory Markers in Inflammatory Bowel Diseases
por: Apolit, Cécile, et al.
Publicado: (2022) -
RNA sequencing analysis of activated macrophages treated with the anti-HIV ABX464 in intestinal inflammation
por: Manchon, Laurent, et al.
Publicado: (2017) -
The Anti-Hiv Candidate Abx464 Dampens Intestinal Inflammation by Triggering Il-22 Production in Activated Macrophages
por: Chebli, Karim, et al.
Publicado: (2017) -
Long lasting control of viral rebound with a new drug ABX464 targeting Rev – mediated viral RNA biogenesis
por: Campos, Noëlie, et al.
Publicado: (2015) -
Safety, Pharmacokinetics, and Antiviral Activity of a Novel HIV Antiviral, ABX464, in Treatment-Naive HIV-Infected Subjects in a Phase 2 Randomized, Controlled Study
por: Steens, Jean-Marc, et al.
Publicado: (2017)